Alkermes (ALKS) said Thursday that schizophrenia patients treated with an experimental tablet called ALKS 3831 reported significantly less weight gain compared to the most commonly prescribed antipsychotic currently in use.
The ALKS 3831 results achieved the main goal of Alkermes’ Phase 3 clinical trial, clearing the way for the biopharma company to file for regulatory approval in the middle of next year.
About the Author Reprints
I am skeptical about any new schizophrenic drugs. Usually the adverse effect is sustainably high than benefits.